title: Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
abstract: Ten patients suffering from chronic premature ventricular complexes (greater than 60/h) were treated orally in a double-blind crossover study with encainide (50 mg three times a day) and disopyramide (200 mg three times a day), with five 7 day study periods: survey, placebo, encainide or disopyramide, washout placebo and disopyramide or encainide. At the end of each 7 day period, a 12 lead electrocardiogram, a 48 hour ambulatory electrocardiogram and a treadmill exercise test were performed. Blood levels of encainide and its metabolites and of disopyramide were measured at the end of each treatment (steady state). Drug efficacy was assessed by: 1) more than 80% reduction in the number of premature ventricular complexes per 24 hours, and 2) absence of ventricular tachycardia. Encainide was effective in four patients (complete suppression of premature ventricular complexes) and ineffective in five. One patient who showed a 92% reduction in the number of premature ventricular complexes developed sustained ventricular tachycardia after 24 hours of treatment. Disopyramide was effective in three patients (greater than 80% reduction in the number of premature ventricular complexes) and ineffective in seven patients. With encainide, the percent increase in PR, QRS and QT interval duration was, respectively: 32.7 (p less than 0.001), 30.8 (p less than 0.001) and 10.6% (p less than 0.01). With disopyramide this increase was not significant. Despite the variability of drug blood levels, a relation between blood levels and suppression of premature ventricular complexes on the 48 hour ambulatory electrocardiogram was found with encainide, but not with disopyramide.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: J F
authors.initials: JF
authors.lastname: Caron
authors.forename: C C
authors.initials: CC
authors.lastname: Libersa
authors.forename: A R
authors.initials: AR
authors.lastname: Kher
authors.forename: S
authors.initials: S
authors.lastname: Kacet
authors.forename: H
authors.initials: H
authors.lastname: Wanszelbaum
authors.forename: B A
authors.initials: BA
authors.lastname: Dupuis
authors.forename: J M
authors.initials: JM
authors.lastname: Poirier
authors.forename: J P
authors.initials: JP
authors.lastname: Lekieffre
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000813:Anilides / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D005117:Cardiac Complexes, Premature / Q000188:drug therapy / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004206:Disopyramide / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D004311:Double-Blind Method; D004562:Electrocardiography; D016700:Encainide; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos
chemical_list: D000813:Anilides; D000889:Anti-Arrhythmia Agents; D010919:Placebos; D004206:Disopyramide; D016700:Encainide